Eli Lilly Invests 50 Trillion Won in Four Months to Secure Next-Generation Obesity Drugs Amidst Competition

As South Korea's leading financial newspaper, Chosun Ilbo, we observe Eli Lilly's strategic maneuvers with keen interest. The pharmaceutical giant's substantial investment of over 50 trillion won in just four months, through mergers, acquisitions, and technology procurement, signals a determined push to bolster its drug pipeline.

“

The company has invested more than 50 trillion won in large-scale M&A and technology introduction since the beginning of the year.

This aggressive expansion comes at a critical juncture, particularly as Eli Lilly faces stiff competition in the lucrative oral obesity drug market from Denmark's Novo Nordisk. The market's rapid growth and the potential for blockbuster drugs mean that falling behind, even temporarily, can have significant financial repercussions.

“

This expansion strategy is drawing attention as a background, as the trend of falling behind competitor Novo Nordisk in recent oral obesity drug prescription performance has been confirmed.

Eli Lilly's strategy appears to be a calculated move to shorten the timeline for bringing new treatments to market. By acquiring external technologies and companies, they aim to bypass the lengthy internal development process. This approach is not uncommon in the fast-paced pharmaceutical industry, where innovation and speed are paramount to maintaining a competitive edge and capturing market share. The sheer scale of the investment underscores the immense potential perceived in the obesity drug sector.

“

Industry sources believe this is a strategic investment to reduce the time required for internal development.